Company registration number 13230538 (England and Wales)
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
COMPANY INFORMATION
Directors
Mr G Brown
Mr G Cooper
Company number
13230538
Registered office
14 Brook's Mews
London
United Kingdom
W1K 4DG
Auditor
Azets Audit Services
Epsilon House
The Square
Gloucester Business Park
Gloucester
United Kingdom
GL3 4AD
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
CONTENTS
Page
Directors' report
1 - 2
Independent auditor's report
3 - 5
Profit and loss account
6
Group balance sheet
7
Company balance sheet
8
Group statement of changes in equity
9
Company statement of changes in equity
10
Notes to the financial statements
11 - 27
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 OCTOBER 2024
- 1 -

The directors present their annual report and financial statements for the year ended 31 October 2024.

Principal activities

Athera Healthcare Group Limited is a holding company whose subsidiaries are Athera Healthcare Limited, Net Solving Limited, Newgate Technology Limited, Fingerprint Global Limited, Fingerprint Medical Limited and Medical Standard 1.

 

The principal activities of the group are that of of the provision of software services to the health and medical sector and the provision of information technology consultancy activities.

Results and dividends

The results for the year are set out on page 6.

No ordinary dividends were paid. The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr G Brown
Mr G Cooper
Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 2 -
Company name

The company formally changed its name from Halcyon Group (Holdings) Limited to Athera Healthcare Group Limited on 28 April 2024.

Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
Mr G Cooper
Director
8 September 2025
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
- 3 -
Opinion

We have audited the financial statements of Athera Healthcare Group Limited previously known as Halcyon Group (Holdings) Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 October 2024 which comprise the group profit and loss account, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
- 4 -

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the directors' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
- 5 -

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.

 

We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework.  Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.  This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.

 

In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:

 

 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation.  This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance.  The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Steve Burke (Senior Statutory Auditor)
For and on behalf of Azets Audit Services
18 September 2025
Chartered Accountants
Statutory Auditor
Epsilon House
The Square
Gloucester Business Park
Gloucester
United Kingdom
GL3 4AD
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
GROUP PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 OCTOBER 2024
- 6 -
2024
2023
Notes
£
£
Turnover
2,900,763
2,125,509
Cost of sales
(460,648)
(288,681)
Gross profit
2,440,115
1,836,828
Administrative expenses
(3,303,406)
(2,221,888)
Exceptional item
3
(67,956)
-
0
Operating loss
(931,247)
(385,060)
Interest receivable and similar income
7,036
4,846
Interest payable and similar expenses
(192,728)
(154,163)
Loss before taxation
(1,116,939)
(534,377)
Tax on loss
5
152,699
(141,761)
Loss for the financial year
(964,240)
(676,138)
Loss for the financial year is all attributable to the owners of the parent company.
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
GROUP BALANCE SHEET
AS AT
31 OCTOBER 2024
31 October 2024
- 7 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
6
6,986,461
5,544,567
Tangible assets
7
18,146
39,198
7,004,607
5,583,765
Current assets
Stocks
75,584
39,830
Debtors
10
646,202
578,858
Cash at bank and in hand
1,232,984
1,743,429
1,954,770
2,362,117
Creditors: amounts falling due within one year
11
(1,695,426)
(1,296,725)
Net current assets
259,344
1,065,392
Total assets less current liabilities
7,263,951
6,649,157
Creditors: amounts falling due after more than one year
12
(1,637,265)
(1,826,361)
Provisions for liabilities
14
(330,000)
(442,000)
Net assets
5,296,686
4,380,796
Capital and reserves
Called up share capital
5,062
578
Share premium account
1,999,553
5,120,851
Capital redemption reserve
16
-
0
Profit and loss reserves
3,292,055
(740,633)
Total equity
5,296,686
4,380,796

These financial statements have been prepared in accordance with the provisions applicable to groups and companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 8 September 2025 and are signed on its behalf by:
08 September 2025
Mr G Cooper
Director
Company registration number 13230538 (England and Wales)
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
COMPANY BALANCE SHEET
AS AT 31 OCTOBER 2024
31 October 2024
- 8 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
8
793,001
793,001
Current assets
Debtors
10
6,109,890
4,167,560
Cash at bank and in hand
97,775
160,508
6,207,665
4,328,068
Creditors: amounts falling due within one year
11
(10,590)
(2,010)
Net current assets
6,197,075
4,326,058
Net assets
6,990,076
5,119,059
Capital and reserves
Called up share capital
5,062
578
Share premium account
1,999,553
5,120,851
Capital redemption reserve
16
-
0
Profit and loss reserves
4,985,445
(2,370)
Total equity
6,990,076
5,119,059

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £9,113 (2023 - £360 loss).

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 8 September 2025 and are signed on its behalf by:
08 September 2025
Mr G Cooper
Director
Company registration number 13230538 (England and Wales)
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2024
- 9 -
Share capital
Share premium account
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 November 2022
100
1,374,917
-
0
(64,495)
1,310,522
Year ended 31 October 2023:
Loss and total comprehensive income
-
-
-
(676,138)
(676,138)
Issue of share capital
478
3,745,934
-
-
3,746,412
Balance at 31 October 2023
578
5,120,851
-
0
(740,633)
4,380,796
Year ended 31 October 2024:
Loss and total comprehensive income
-
-
-
(964,240)
(964,240)
Issue of share capital
4,500
1,999,553
-
-
2,004,053
Purchase of own shares
(16)
-
16
(123,923)
(123,923)
Capital reduction
-
(5,120,851)
-
5,120,851
-
0
Balance at 31 October 2024
5,062
1,999,553
16
3,292,055
5,296,686
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2024
- 10 -
Share capital
Share premium account
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 November 2022
100
1,374,917
-
0
(2,010)
1,373,007
Year ended 31 October 2023:
Loss and total comprehensive income for the year
-
-
-
(360)
(360)
Issue of share capital
478
3,745,934
-
-
3,746,412
Balance at 31 October 2023
578
5,120,851
-
0
(2,370)
5,119,059
Year ended 31 October 2024:
Profit and total comprehensive income
-
-
-
(9,113)
(9,113)
Issue of share capital
4,500
1,999,553
-
-
2,004,053
Purchase of own shares
(16)
-
16
(123,923)
(123,923)
Capital reduction
-
(5,120,851)
-
5,120,851
-
0
Balance at 31 October 2024
5,062
1,999,553
16
4,985,445
6,990,076
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
- 11 -
1
Accounting policies
Company information

Athera Healthcare Group Limited previously known as Halcyon Group (Holdings) Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is 14 Brooks Mews, London, United Kingdom, W1K 4DG.

 

The group consists of Athera Healthcare Group Limited previously known as Halcyon Group (Holdings) Limited and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

 

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

1.3
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Athera Healthcare Group Limited previously known as Halcyon Group (Holdings) Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 31 October 2024. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 12 -

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

1.4
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.6
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.7
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 13 -
1.8
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

 

Costs associated with the development of internally generated intangible assets are recognised once:

• The technical feasibility of completing the asset for use or sale has been confirmed;

• There is intention and ability to use or sell the asset;

• Future economic benefits are probable;

• There is certainty regarding the ability to complete the development for use or sale; and

• The costs attributable to the development of the asset can be reliably measured.

 

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
10% to 25% straight line method
1.9
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery etc.
25% to 33% straight line method, or 15-25% reducing balance method

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.10
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 14 -
1.11
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.12
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.13
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.14
Financial instruments

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 15 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 16 -
Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.15
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.16
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 17 -
1.17
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.18
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.19
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

1.20
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.21

Provisions

Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

 

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in or in the period in which it arises.

1.22

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

1.23

Exceptional items

Exceptional items are those which are separately identified by virtue of their size or nature to allow a full understanding of the underlying performance of the company.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 18 -
2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Amortisation of intangibles

The annual amortisation charge for intangible assets is sensitive to changes in relation to the value of works performed on software as these assets relate to capitalised staff costs. The useful economic life is assessed annually and is amended as necessary based on the value of the work the intangible assets relate to.

 

The directors have made key assumptions regarding the useful life of intangible assets and have determined that they have a useful life of 4 to 10 years. The period applied is considered appropriate to match the anticipated future profitability arising from the associated software developed and from continued future growth within the trade of the group.

Capitalisation of software costs

Staff time is incurred in developing software assets. This is then capitalised as the income this will generate is spread over the life of the associated product and service line. The amount of staff cost capitalised is based upon estimate of time incurred in these areas of work and is reviewed annually. This is a subjective area due to estimates of time, as well as nature of internally generated intangible assets.

3
Exceptional item
2024
2023
£
£
Expenditure
Exceptional items
67,956
-

Included within exceptional items are costs in relation to the acquisition and subsequent restructuring of a subsidiary company of £67,956 (2024: £Nil).

4
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2024
2023
2024
2023
Number
Number
Number
Number
Total
44
27
2
2
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 19 -
5
Taxation
2024
2023
£
£
Current tax
Adjustments in respect of prior periods
(38,753)
137,969
Deferred tax
Origination and reversal of timing differences
(113,946)
3,792
Total tax (credit)/charge
(152,699)
141,761

The actual (credit)/charge for the year can be reconciled to the expected credit for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Loss before taxation
(1,116,939)
(534,377)
Expected tax credit based on the standard rate of corporation tax in the UK of 25.00% (2023: 22.50%)
(279,235)
(120,235)
Tax effect of expenses that are not deductible in determining taxable profit
7,363
1,781
Change in unrecognised deferred tax assets
91,589
26,751
Adjustments in respect of prior years
(33,632)
(4,612)
Amortisation on assets not qualifying for tax allowances
118,227
84,819
Under/(over) provided in prior years
(38,753)
137,969
Deferred tax adjustments in respect of prior years
(1,946)
1,498
Other including effect of changes in rate
(16,312)
13,790
Taxation (credit)/charge
(152,699)
141,761
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 20 -
6
Intangible fixed assets
Group
Goodwill
Development costs
Total
£
£
£
Cost
At 1 November 2023
4,299,151
2,564,170
6,863,321
Additions
1,721,544
648,681
2,370,225
At 31 October 2024
6,020,695
3,212,851
9,233,546
Amortisation and impairment
At 1 November 2023
564,594
754,160
1,318,754
Amortisation charged for the year
472,906
455,425
928,331
At 31 October 2024
1,037,500
1,209,585
2,247,085
Carrying amount
At 31 October 2024
4,983,195
2,003,266
6,986,461
At 31 October 2023
3,734,557
1,810,010
5,544,567
The company had no intangible fixed assets at 31 October 2024 or 31 October 2023.

All assets of the group are secured by fixed and floating charges relating to the group bank loan facility.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 21 -
7
Tangible fixed assets
Group
Plant and machinery etc
£
Cost
At 1 November 2023
110,273
Additions
87,398
Disposals
(60,005)
At 31 October 2024
137,666
Depreciation and impairment
At 1 November 2023
71,075
Depreciation charged in the year
15,309
Eliminated in respect of disposals
(43,230)
Transfers
76,366
At 31 October 2024
119,520
Carrying amount
At 31 October 2024
18,146
At 31 October 2023
39,198
The company had no tangible fixed assets at 31 October 2024 or 31 October 2023.

All assets of the group are secured by fixed and floating charges relating to the group bank loan facility.

8
Fixed asset investments
Group
Company
2024
2023
2024
2023
£
£
£
£
Shares in group undertakings and participating interests
-
-
793,001
793,001
-
0
-
0
793,001
793,001
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
8
Fixed asset investments
(Continued)
- 22 -
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 November 2023 and 31 October 2024
793,001
Carrying amount
At 31 October 2024
793,001
At 31 October 2023
793,001
9
Subsidiaries

Details of the company's subsidiaries at 31 October 2024 are as follows:

Name of undertaking
Address
Class of
% Held
shares held
Direct
Indirect
Net Solving Limited
1
Ordinary
0
100.00
Fingerprint Global Limited
2
Ordinary
0
100.00
Fingerprint Medical Limited
1
Ordinary
0
100.00
Medical Standard 1
1
Ordinary
0
100.00
Athera Healthcare Limited
1
Ordinary
100.00
-
Newgate Technology Limited
1
Ordinary
0
100.00

Registered office addresses (all UK unless otherwise indicated):

1
14 Brook's Mews, London, W1K 4DG, United Kingdom
2
Abercorn House, 79 Renfrew Road, Paisley, PA3 4DA, United Kingdom

The group acquired 100% of the ordinary share capital of Newgate Technology Limited on 1 August 2024.

 

Athera Healthcare Limited changed its name from Halcyon (Bidco) Limited on 30 April 2024.

ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 23 -
10
Debtors
Group
Company
2024
2023
2024
2023
as restated
Amounts falling due within one year:
£
£
£
£
Trade debtors
369,731
196,385
-
0
-
0
Corporation tax recoverable
66,613
-
0
-
0
-
0
Amounts owed by group
-
0
-
0
6,109,793
4,067,373
Other debtors
193,228
365,843
97
100,187
629,572
562,228
6,109,890
4,167,560
Amounts falling due after more than one year:
Other debtors
16,630
16,630
-
-
Total debtors
646,202
578,858
6,109,890
4,167,560

Amounts owed by group are unsecured, interest free and repayable on demand.

 

All assets of the group are secured by fixed and floating charges relating to the group bank loan facility.

11
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
£
£
£
£
Bank loans
189,119
171,398
-
0
-
0
Trade creditors
168,374
72,375
-
0
-
0
Amounts owed to group undertakings
-
0
-
0
810
810
Corporation tax payable
120,509
148,893
-
0
-
0
Other taxation and social security
161,903
136,646
-
0
-
0
Other creditors
1,055,521
767,413
9,780
1,200
1,695,426
1,296,725
10,590
2,010

Amounts owed to group undertakings are unsecured, interest free and repayable on demand.

12
Creditors: amounts falling due after more than one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans and overdrafts
1,637,265
1,826,361
-
0
-
0
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 24 -
13
Loans and overdrafts
Group
Company
2024
2023
2024
2023
£
£
£
£
Bank loans
1,826,384
1,997,759
-
0
-
0
Payable within one year
189,119
171,398
-
-
Payable after one year
1,637,265
1,826,361
-
0
-
0

Bank loans of £231,286 (2023: £332,313) bear a fixed interest rate of 8.5% and are repayable by quarterly instalments, with the final payment due August 2026.

 

Bank loans of £519,408 (2023: £516,258) bear a fixed interest rate of 8.5% and are due for repayment August 2026.

 

Bank loans of £351,220 (2023: £430,604) bear a fixed interest rate of 9.5% and are repayable by quarterly instalments, with the final payment due February 2028.

 

Bank loans of £724,469 (2023: 718,584) bear a fixed interest rate of 9.5% and are due for repayment February 2028.

 

All amounts recognised are stated net of applicable arrangement fees.

14
Provisions for liabilities
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Deferred tax liabilities
15
330,000
442,000
-
0
-
0
15
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2024
2023
Group
£
£
Accelerated capital allowances
3,086
11,412
Tax losses
(171,122)
(20,153)
Other timing differences
498,036
450,741
330,000
442,000
The company has no deferred tax assets or liabilities.
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
15
Deferred taxation
(Continued)
- 25 -
Group
Company
2024
2024
Movements in the year:
£
£
Liability at 1 November 2023
442,000
-
Credit to profit or loss
(113,946)
-
Other
1,946
-
Liability at 31 October 2024
330,000
-

Based on the forecast short-term utilisation of taxable losses, no deferred tax asset has been recognised in relation to the available taxable losses of the company. Accordingly, the group has an unrecognised deferred tax asset in the region of £167,000 (2023: £33,000) and company £2,000 (2023: £90) based on there being no anticipated future change to the current main tax rate of 25%.

16
Acquisition of a business

On 1 August 2024 the group acquired 100 percent of the issued capital of Newgate Technology Limited.

Book Value
Adjustments
Book value
Net assets acquired
£
£
£
Property, plant and equipment
4,797
-
4,797
Inventories
30,601
-
30,601
Trade and other receivables
302,832
-
302,832
Cash and cash equivalents
85,021
-
85,021
Trade and other payables
(282,943)
-
(282,943)
Deferred tax
(1,946)
-
(1,946)
Total identifiable net assets
138,362
-
138,362
Goodwill
1,721,544
Total consideration
1,859,906
The consideration was satisfied by:
£
Cash
1,414,800
Deferred consideration
66,613
Associated fees
378,493
1,859,906
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
16
Acquisition of a business
(Continued)
- 26 -
Contribution by the acquired business for the reporting period included in the group statement of comprehensive income since acquisition:
£
Turnover
175,760
Loss after tax
(97,668)
17
Operating lease commitments
Lessee

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

Group
Company
2024
2023
2024
2023
£
£
£
£
Within one year
40,000
509
-
-
Between two and five years
160,000
-
-
-
In over five years
133,333
-
-
-
333,333
509
-
-

An agreement has since been reached with the landlord for the above noted lease. As a result, it is anticipated that this lease shall be terminated early and no amounts disclosed as due in more than one year shall become payable.

18
Financial commitments, guarantees and contingent liabilities

As at 31 October 2024 the group had other guarantees, contingencies and commitments of £Nil (2023: £Nil).

 

As at 31 October 2024 the company had total guarantees, contingencies and commitments of £Nil (2023:

£Nil).

19
Directors' transactions
Description
% Rate
Opening balance
Amounts repaid
Closing balance
£
£
£
Unpaid share capital
100,100
(100,100)
-
100,100
(100,100)
-
ATHERA HEALTHCARE GROUP LIMITED (FORMERLY HALCYON GROUP (HOLDINGS) LIMITED)
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 27 -
20
Controlling party

Aliter Capital II LLP is the company's ultimate controlling party, a limited liability partnership whose registered office is 14 Brook's Mews, London, W1K 4DG.

 

2024-10-312023-11-01falsefalseCCH SoftwareCCH Accounts Production 2025.100Mr G BrownMr G Cooperfalse13230538bus:Consolidated2023-11-012024-10-31132305382023-11-012024-10-3113230538bus:Director12023-11-012024-10-3113230538bus:Director22023-11-012024-10-3113230538bus:RegisteredOffice2023-11-012024-10-3113230538bus:Consolidated2024-10-31132305382024-10-3113230538bus:Consolidated2022-11-012023-10-3113230538bus:Consolidated12023-11-012024-10-3113230538bus:Consolidated12022-11-012023-10-31132305382022-11-012023-10-3113230538bus:Consolidated2023-10-3113230538core:NetGoodwillbus:Consolidated2024-10-3113230538core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-10-3113230538core:NetGoodwillbus:Consolidated2023-10-3113230538core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2023-10-3113230538core:OtherPropertyPlantEquipmentbus:Consolidated2024-10-3113230538core:OtherPropertyPlantEquipmentbus:Consolidated2023-10-31132305382023-10-3113230538core:ShareCapitalbus:Consolidated2024-10-3113230538core:ShareCapitalbus:Consolidated2023-10-3113230538core:SharePremiumbus:Consolidated2024-10-3113230538core:SharePremiumbus:Consolidated2023-10-3113230538core:CapitalRedemptionReservebus:Consolidated2024-10-3113230538core:CapitalRedemptionReservebus:Consolidated2023-10-3113230538core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-10-3113230538core:ShareCapital2024-10-3113230538core:ShareCapital2023-10-3113230538core:SharePremium2024-10-3113230538core:SharePremium2023-10-3113230538core:CapitalRedemptionReserve2024-10-3113230538core:CapitalRedemptionReserve2023-10-3113230538core:RetainedEarningsAccumulatedLosses2024-10-3113230538core:RetainedEarningsAccumulatedLosses2023-10-3113230538core:ShareCapitalbus:Consolidated2022-10-3113230538core:SharePremiumbus:Consolidated2022-10-3113230538core:CapitalRedemptionReservebus:Consolidated2022-10-3113230538core:RetainedEarningsAccumulatedLossesbus:Consolidated2022-10-3113230538core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-10-3113230538core:ShareCapital2022-10-3113230538core:SharePremium2022-10-3113230538core:CapitalRedemptionReserve2022-10-3113230538core:RetainedEarningsAccumulatedLosses2022-10-3113230538core:ShareCapitalbus:Consolidated2022-11-012023-10-3113230538core:SharePremiumbus:Consolidated2022-11-012023-10-3113230538core:ShareCapitalbus:Consolidated2023-11-012024-10-3113230538core:SharePremiumbus:Consolidated2023-11-012024-10-3113230538core:ShareCapital2022-11-012023-10-3113230538core:SharePremium2022-11-012023-10-3113230538core:ShareCapital2023-11-012024-10-3113230538core:SharePremium2023-11-012024-10-3113230538core:Goodwill2023-11-012024-10-3113230538core:IntangibleAssetsOtherThanGoodwill2023-11-012024-10-3113230538core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-11-012024-10-3113230538core:ComputerEquipment2023-11-012024-10-3113230538core:UKTaxbus:Consolidated2023-11-012024-10-3113230538core:UKTaxbus:Consolidated2022-11-012023-10-3113230538bus:Consolidated22023-11-012024-10-3113230538bus:Consolidated22022-11-012023-10-3113230538bus:Consolidated32023-11-012024-10-3113230538bus:Consolidated32022-11-012023-10-3113230538core:NetGoodwillbus:Consolidated2023-10-3113230538core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2023-10-3113230538bus:Consolidated2023-10-3113230538core:Goodwillbus:Consolidated2023-11-012024-10-3113230538core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2023-11-012024-10-3113230538core:NetGoodwillbus:Consolidated2023-11-012024-10-3113230538core:OtherPropertyPlantEquipmentbus:Consolidated2023-10-3113230538core:OtherPropertyPlantEquipmentbus:Consolidated2023-11-012024-10-3113230538core:Subsidiary12023-11-012024-10-3113230538core:Subsidiary22023-11-012024-10-3113230538core:Subsidiary32023-11-012024-10-3113230538core:Subsidiary42023-11-012024-10-3113230538core:Subsidiary52023-11-012024-10-3113230538core:Subsidiary62023-11-012024-10-3113230538core:Subsidiary112023-11-012024-10-3113230538core:Subsidiary222023-11-012024-10-3113230538core:Subsidiary332023-11-012024-10-3113230538core:Subsidiary442023-11-012024-10-3113230538core:Subsidiary552023-11-012024-10-3113230538core:Subsidiary662023-11-012024-10-3113230538core:WithinOneYearbus:Consolidated2024-10-3113230538core:WithinOneYearbus:Consolidated2023-10-3113230538core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3113230538core:CurrentFinancialInstrumentscore:WithinOneYear2023-10-3113230538core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-10-3113230538core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2023-10-3113230538core:Non-currentFinancialInstrumentscore:AfterOneYear2024-10-3113230538core:Non-currentFinancialInstrumentscore:AfterOneYear2023-10-3113230538core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-10-3113230538core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-10-3113230538core:CurrentFinancialInstrumentsbus:Consolidated2024-10-3113230538core:CurrentFinancialInstrumentsbus:Consolidated2023-10-3113230538core:CurrentFinancialInstruments2024-10-3113230538core:CurrentFinancialInstruments2023-10-3113230538bus:PrivateLimitedCompanyLtd2023-11-012024-10-3113230538bus:FRS1022023-11-012024-10-3113230538bus:Audited2023-11-012024-10-3113230538bus:ConsolidatedGroupCompanyAccounts2023-11-012024-10-3113230538bus:FullAccounts2023-11-012024-10-31xbrli:purexbrli:sharesiso4217:GBP